Search Results - "Jegede, Opeyemi"

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma by Braun, David A., Hou, Yue, Bakouny, Ziad, Ficial, Miriam, Sant’ Angelo, Miriam, Forman, Juliet, Ross-Macdonald, Petra, Berger, Ashton C., Jegede, Opeyemi A., Elagina, Liudmilla, Steinharter, John, Sun, Maxine, Wind-Rotolo, Megan, Pignon, Jean-Christophe, Cherniack, Andrew D., Lichtenstein, Lee, Neuberg, Donna, Catalano, Paul, Freeman, Gordon J., Sharpe, Arlene H., McDermott, David F., Van Allen, Eliezer M., Signoretti, Sabina, Wu, Catherine J., Shukla, Sachet A., Choueiri, Toni K.

“…PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain…”
Get full text

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma by Nassar, Amin H., Mouw, Kent W., Jegede, Opeyemi, Shinagare, Atul B., Kim, Jaegil, Liu, Chia-Jen, Pomerantz, Mark, Harshman, Lauren C., Van Allen, Eliezer M., Wei, Xiao X., McGregor, Bradley, Choudhury, Atish D., Preston, Mark A., Dong, Fei, Signoretti, Sabina, Lindeman, Neal I., Bellmunt, Joaquim, Choueiri, Toni K., Sonpavde, Guru, Kwiatkowski, David J.

“…Background In metastatic urothelial carcinoma (mUC), predictive biomarkers that correlate with response to immune checkpoint inhibitors (ICIs) are lacking…”
Get full text

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) by Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans

“…To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in…”
Get full text

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma by Ficial, Miriam, Jegede, Opeyemi A, Sant'Angelo, Miriam, Hou, Yue, Flaifel, Abdallah, Pignon, Jean-Christophe, Braun, David A, Wind-Rotolo, Megan, Sticco-Ivins, Maura A, Catalano, Paul J, Freeman, Gordon J, Sharpe, Arlene H, Hodi, F Stephen, Motzer, Robert J, Wu, Catherine J, Atkins, Michael B, McDermott, David F, Shukla, Sachet A, Choueiri, Toni K, Signoretti, Sabina

“…We sought to validate levels of CD8 tumor-infiltrating cells (TIC) expressing PD-1 but not TIM-3 and LAG-3 (IF biomarker; Pignon and colleagues, 2019) and to…”
Get full text

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial by Regan, Meredith M, Jegede, Opeyemi A, Mantia, Charlene M, Powles, Thomas, Werner, Lillian, Motzer, Robert J, Tannir, Nizar M, Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H, Plimack, Elizabeth R, Choueiri, Toni K, Rini, Brian I, Hammers, Hans J, Escudier, Bernard, Albiges, Laurence, Huo, Stephen, Del Tejo, Viviana, Stwalley, Brian, Atkins, Michael B, McDermott, David F

“…Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may…”
Get full text

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial by Pignon, Jean-Christophe, Jegede, Opeyemi, Shukla, Sachet A, Braun, David A, Horak, Christine E, Wind-Rotolo, Megan, Ishii, Yuko, Catalano, Paul J, Grosha, Jonian, Flaifel, Abdallah, Novak, Jesse S, Mahoney, Kathleen M, Freeman, Gordon J, Sharpe, Arlene H, Hodi, F Stephen, Motzer, Robert J, Choueiri, Toni K, Wu, Catherine J, Atkins, Michael B, McDermott, David F, Signoretti, Sabina

“…Immune-related RECIST (irRECIST) were designed to capture atypical responses seen with immunotherapy. We hypothesized that, in patients with metastatic clear…”
Get full text

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma by Correa, Andres F., Jegede, Opeyemi A., Haas, Naomi B., Flaherty, Keith T., Pins, Michael R., Adeniran, Adebowale, Messing, Edward M., Manola, Judith, Wood, Christopher G., Kane, Christopher J., Jewett, Michael A.S., Dutcher, Janice P., DiPaola, Robert S., Carducci, Michael A., Uzzo, Robert G.

“…Risk stratification for localized renal cell carcinoma (RCC) relies heavily on retrospective models, limiting their generalizability to contemporary cohorts…”
Get full text

Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma by Kahl, Brad S, Jegede, Opeyemi A, Peterson, Christopher, Swinnen, Lode J, Habermann, Thomas M, Schuster, Stephen J, Weiss, Matthias, Fishkin, Paul A, Fenske, Timothy S, Williams, Michael E

“…JCO In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies…”
Get full text

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma by Tsai, Leo L, Bhatt, Rupal S, Strob, Meaghan F, Jegede, Opeyemi A, Sun, Maryellen R M, Alsop, David C, Catalano, Paul, McDermott, David, Robson, Philip M, Atkins, Michael B, Pedrosa, Ivan

“…Background Tumor perfusion may inform therapeutic response and resistance in metastatic renal cell carcinoma (RCC) treated with antiangiogenic therapy. Purpose…”
Get full text

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial by Lee, Ziho, Jegede, Opeyemi A, Haas, Naomi B, Pins, Michael R, Messing, Edward M, Manola, Judith, Wood, Christopher G, Kane, Christopher J, Jewett, Michael A S, Flaherty, Keith T, Dutcher, Janice P, DiPaola, Robert S, Uzzo, Robert G

“…We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic…”
Get full text

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients by Denize, Thomas, Jegede, Opeyemi A, Matar, Sayed, El Ahmar, Nourhan, West, Destiny J, Walton, Emily, Bagheri, Aseman Sheshdeh, Savla, Varunika, Nabil Laimon, Yasmin, Gupta, Saurabh, Vemula, Sai Vikram, Braun, David A, Burke, Kelly P, Catalano, Paul J, Freeman, Gordon J, Motzer, Robert J, Atkins, Michael B, McDermott, David F, Sharpe, Arlene H, Choueiri, Toni K, Signoretti, Sabina

“…Programmed cell death protein 1 (PD-1) expression on CD8+TIM-3-LAG-3- tumor-infiltrating cells predicts positive response to PD-1 blockade in metastatic…”
Get full text

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 by Stearns, Vered, Jegede, Opeyemi A, Chang, Victor T-S, Skaar, Todd C, Berenberg, Jeffrey L, Nand, Ranveer, Shafqat, Atif, Jacobs, Nisha L, Luginbuhl, William, Gilman, Paul, Benson, 3rd, Al B, Goodman, Judie R, Buchschacher, Jr, Gary L, Henry, N Lynn, Loprinzi, Charles L, Flynn, Patrick J, Mitchell, Edith P, Fisch, Michael J, Sparano, Joseph A, Wagner, Lynne I

“…Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been…”
Get full text

Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent by Yang, Eddy S, Nassar, Amin H, Adib, Elio, Jegede, Opeyemi A, Alaiwi, Sarah Abou, Manna, Deborah L Della, Braun, David A, Zarei, Mahsa, Du, Heng, Pal, Sumanta K, Naik, Gurudatta, Sonpavde, Guru P

“…Everolimus monotherapy use for metastatic renal cell carcinoma (mRCC) has diminished due to recent approvals of immune checkpoint and VEGF inhibitors. We…”
Get full text

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL by Smith, Mitchell R., Jegede, Opeyemi A., Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T., Hsi, Eric D., Witzig, Thomas, Dave, Sandeep, Scott, David, Hanson, Curtis, Kostakoglu Shields, Lale, Abdel-Samad, Nizar, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo F., Al Baghdadi, Tareq, Blum, Kristie A., Romer, Mark D., Inwards, David J., Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John P., Kahl, Brad S.

“…•MCL BR-based induction and R-based maintenance gave 88% overall response rate, 91% measurable residual disease–negative and median PFS 6.9 years.•Neither…”
Get full text

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial by Steuer, Conor E, Jegede, Opeyemi A, Dahlberg, Suzanne E, Wakelee, Heather A, Keller, Steven M, Tester, William J, Gandara, David R, Graziano, Stephen L, Adjei, Alex A, Butts, Charles A, Ramalingam, Suresh S, Schiller, Joan H

“…Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in…”
Get more information

Cardiovascular complications in COVID‐19 patients with or without diabetes mellitus by Abe, Temidayo, Egbuche, Obiora, Igwe, Joseph, Jegede, Opeyemi, Wagle, Bivek, Olanipekun, Titilope, Onwuanyi, Anekwe

“…Introduction Coronavirus disease 2019 (COVID‐19) has become a major global crisis. Preliminary reports have, in general, indicated worse outcomes in diabetes…”
Get full text

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) by Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, Mcdermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Einstein, David, Catalano, Paul J, Hammers, Hans, Regan, Meredith M

“…BackgroundAs part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the…”
Get full text

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214 by Mantia, Charlene M, Jegede, Opeyemi A, Plimack, Elizabeth R, Powles, Thomas, Motzer, Robert J, Tannir, Nizar M, Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H, Choueiri, Toni K, Rini, Brian I, Hammers, Hans J, Escudier, Bernard, Albigès, Laurence, Rosenblatt, Lisa, Atkins, Michael B, Regan, Meredith M, McDermott, David F

“…BackgroundImmunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed…”
Get full text

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) by Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans

“…BackgroundTo determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the…”
Get full text

Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury by Egbuche, Obiora, Abe, Temidayo, Nwokike, Shirley I, Jegede, Opeyemi, Mezue, Kenechukwu, Olanipekun, Titilope, Onuorah, Ifeoma, Echols, Melvin R

“…In-hospital acute kidney injury (IH-AKI) has been reported in a significant proportion of patients with COVID-19 and is associated with increased disease…”
Get full text